J. Vornov

发表

Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors.

B. Slusher, J. Vornov, K. Hollinger, 2016, Advances in pharmacology.

Sedation with GPI 15715, a water-soluble prodrug of propofol, using target-controlled infusion in volunteers.

C. Jeleazcov, J. Fechner, H. Schwilden, 2005, Anesthesia and analgesia.

Enhancement of NMDA receptor-mediated neurotoxicity in the hippocampal slice by depolarization and ischemia

J. Coyle, J. Vornov, 1991, Brain Research.

FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.

M. Marohn, Xuhang Li, B. Slusher, 2016, JCI insight.

Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.

T. Tsukamoto, B. Slusher, J. Vornov, 2006, Advances in experimental medicine and biology.

Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury

F. Tortella, R. Traystman, M. Yudkoff, 1999, Nature Medicine.

Inhibition of virus-induced neuronal apoptosis by Bax

S. Korsmeyer, S. Korsmeyer, G. Oyler, 1999, Nature Medicine.

Blood Flow, Energy Failure, and Vulnerability to Stroke

J. Vornov, 1999 .

Protective Effects of Extracellular Acidosis and Blockade of Sodium/Hydrogen Ion Exchange During Recovery from Metabolic Inhibition in Neuronal Tissue Culture

J. Vornov, A. Thomas, A. G. Thomas, 1996, Journal of neurochemistry.

Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.

Yanke Yu, B. Slusher, B. Littlefield, 2016, Cancer research.

Toxicity induced by a polyglutamated folate analog is attenuated by NAALADase inhibition

B. Slusher, J. Vornov, A. Thomas, 1999, Brain Research.

AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 1): pharmacokinetics.

M. Struys, A. Vanluchene, L. V. Van Bortel, 2005, Anesthesiology.

Cerebellar top-of-the-basilar syndrome

M. Geschwind, I. Silverman, J. Vornov, 1998, Clinical neurology and neurosurgery (Dutch-Flemish ed. Print).

Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers

B. Slusher, J. Vornov, K. Wozniak, 2015, Journal of Translational Medicine.

Ghrelin agonist HM01 attenuates chemotherapy‐induced neurotoxicity in rodent models

Y. Liu, G. Cavaletti, A. Chiorazzi, 2018, European journal of pharmacology.

The regional vulnerability to hypoglycemia-induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK-801

J. Coyle, R. Tasker, J. Vornov, 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Toxic NMDA‐Receptor Activation Occurs During Recovery in a Tissue Culture Model of Ischemia

J. Vornov, 1995, Journal of neurochemistry.

Neurotoxicity of Acute Glutamate Transport Blockade Depends on Coactivation of Both NMDA and AMPA/Kainate Receptors in Organotypic Hippocampal Cultures

R. Tasker, J. Vornov, John Park, 1995, Experimental Neurology.

AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 2): pharmacodynamics and safety.

M. Struys, A. Vanluchene, L. V. Van Bortel, 2010, Anesthesiology.

Regional Vulnerability to Endogenous and Exogenous Oxidative Stress in Organotypic Hippocampal Culture

J. Vornov, A. Thomas, John Park, 1998, Experimental Neurology.

Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism

B. Slusher, J. Vornov, K. Wozniak, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Ion channels and exchangers that mediate ischemic neuronal injury.

J. Vornov, 1998, Current Opinion in Neurology.

Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats

J. Fechner, H. Schwilden, M. Schywalsky, 2003, European journal of anaesthesiology.

Glutamate Neurotoxicity and the Inhibition of Protein Synthesis in the Hippocampal Slice

J. Coyle, J. Vornov, 1991, Journal of neurochemistry.

Brainstem projections to the normal and noradrenergically hyperinnervated trigeminal motor nucleus

J. Sutin, J. Vornov, 1983, The Journal of comparative neurology.

We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine

K. Lemberg, B. Slusher, J. Vornov, 2018, Molecular Cancer Therapeutics.

Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers

B. Slusher, J. Vornov, K. Wozniak, 2015, Journal of Translational Medicine.

7. The non-excitatory mechanisms of glutamate induced neurotoxicity

T. Murphy, J. Coyle, J. Vornov, 1991, Epilepsy Research.

Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist

R. Mazhari, N. Liverton, L. Kiss, 2015, Pharmacology research & perspectives.

Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery.

Y. Liu, G. Cavaletti, S. Feinstein, 2018, Cancer research.

The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

D. Hilt, J. Gerven, E. Bortey, 2005, British journal of clinical pharmacology.

N-Acetylated alpha-linked acidic dipeptidase converts N-acetylaspartylglutamate from a neuroprotectant to a neurotoxin.

B. Slusher, J. Vornov, J. Olkowski, 2000, The Journal of pharmacology and experimental therapeutics.

Glutamate carboxypeptidase II inhibition as a novel therapeutic target.

T. Tsukamoto, B. Slusher, J. Vornov, 2003, Advances in experimental medicine and biology.

Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain

B. Slusher, J. Vornov, K. Hollinger, 2019, Neurochemical Research.

Direct observation of the agonist-specific regional vulnerability to glutamate, NMDA, and kainate neurotoxicity in organotypic hippocampal cultures

J. Coyle, R. Tasker, J. Vornov, 1991, Experimental Neurology.

Noradrenergic hyperinnervation of the motor trigeminal nucleus: alterations in membrane properties and responses to synaptic input

J. Sutin, J. Vornov, 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain

B. Slusher, J. Vornov, K. Hollinger, 2019, Neurochemical Research.

The Orally Active Glutamate Carboxypeptidase II Inhibitor E2072 Exhibits Sustained Nerve Exposure and Attenuates Peripheral Neuropathy

T. Tsukamoto, B. Slusher, J. Vornov, 2012, Journal of Pharmacology and Experimental Therapeutics.

Selective release ofN-acetylaspartylglutamate from rat optic nerve terminals in vivo

J. Coyle, G. Tsai, J. Deshpande, 1990, Brain Research.

Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers.

J. Fechner, H. Schwilden, J. Schüttler, 2003, Anesthesiology.

Objectives of Biomarkers in Early Drug Development Biomarkers for Pharmacological Effects Biomarkers for (patho)physiological Principle Biomarkers for Therapeutic Principle Table 1 Number of Tests within Individual Domains Neuropsychological Domains Neuroleptics Selective Serotonin Re-uptake Inhibit

M. Ferrari, F. Zitman, D. Hilt, 2022 .

Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion.

C. Jeleazcov, J. Fechner, H. Schwilden, 2004, Anesthesiology.

Pharmacokinetic/-dynamic modelling of the new propofol prodrug GPI-15715 in rats

H. Schwilden, M. Schywalsky, J. Vornov, 2002 .

Blockade of NAALADase: A Novel Neuroprotective Strategy Based on Limiting Glutamate and Elevating NAAG

T. Tsukamoto, J. Vornov, K. Wozniak, 1999, Annals of the New York Academy of Sciences.

Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats: Retraction

J. Fechner, H. Schwilden, M. Schywalsky, 2003 .